Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Relapsed/Refractory Multiple Myeloma
NCT01794520Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2012
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of venetoclax in multiple myeloma (MM), sponsored by AbbVie Inc.. Started Oct 2012; status: completed.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01794520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01794520.